Immunosuppressive effects of E-series prostaglandins have been demonstrated in many in vitro assays of immune responsiveness as well as in autoimmune diseases. To explore the mechanisms underlying prostaglandin El (PGE1)-associated immunosuppression in autoimmunity, we treated SJL mice immunized to produce immune-mediated interstitial nephritis with PGE1, PGFu, or vehicle alone. Mice receiving PGE1 treatment do not develop interstitial nephritis, nor do they display delayed-type hypersensitivity (DTH) to the immunizing renal tubular antigen preparation. The observed immunosuppression is critically dependent on PGE1 administration during the period of effector T cell induction. We therefore investigated the effect of PGE1 on the in vitro induction of DTH effector T cells reactive to renal tubular antigens (SRTA). PGE1 inhibits effector T cell induction in a dose-dependent, reversible manner, but has no inhibitory effect on fully differentiated DTH effector cells or SRTA-reactive cell lines. The PGE1 effect is indirect and mediated via nonspecific suppressor lymphokines. This suppression can be overcome by recombinant interleukin 1 (IL-i), which suggests a mechanism related to either diminished IL-1 secretion or target cell sensitivity to IL-1.
Introduction
Inhibitory effects of E-series prostaglandins (PGE)' on lymphoid cells in culture have been described by many investigators (1) . Subsequent studies have extended these in vitro observations by examining the protective effect of exogenously administered PGE1 or PGE2 on experimental autoimmune diseases, including several murine models of immune complex glomerulonephritis (2) (3) (4) (5) . Glomerular injury in these models has been attributed to the damage resulting from deposited or locally formed immune complexes, with PGE administration acting either to diminish titers of relevant circulating antibody (4, 5) or to inhibit local antibody or immune complex deposition (2, 3) . Although in some studies quantitative changes in T cell subpopulations have been observed concomitant with PGE therapy (4) (5) (6) , it is uncertain whether these latter findings mediate or have a role in suppression of disease activity. This uncertainty is due in part to lack of a well-defined effector role for auto-sensitized T cells in these models of glomerulonephritis.
We have been interested in characterizing the regulation of antibody and effector T cell function in experimental interstitial nephritis (7) (8) (9) (10) . This renal lesion can be induced in susceptible rodents by immunization with renal tubular basement membranes (RTA) in complete Freund's adjuvant (CFA). In SJL mice, a prototypic susceptible strain, antibodies to tubular basement membrane (aTBM-Ab) are demonstrable in the serum and kidneys 7-10 d after immunization. Interstitial mononuclear cell infiltrates and progressive tubular atrophy with fibrosis develop 8-10 wk later (1 1). This lesion can be transferred to naive mice either with antibodies or T cells from immunized syngeneic donors ( 12) , or with long-term cultured tubular antigen-reactive helper T cells (13) . These cultured helper cells appear not to directly injure the kidney but rather induce, in the naive recipient, Lyt-2', antigen-specific effector T cells, which both mediate delayed-type hypersensitivity (DTH) to soluble tubular antigens as well as tubulo-interstitial injury. The induction of nephritogenic effector T cells can also be carried out in vitro (13) , thus facilitating an analysis of the requirements for and the modulation of effector T cell differentiation.
In the present studies we examined the effect of exogenous PGE1 both on experimental interstitial nephritis, and the in vitro induction of effector cells. Our results demonstrate that PGE, can markedly impair histologic interstitial nephritis, as well as DTH reactivity to tubular antigen, but only when administered from the time of immunization. The in vitro studies further indicate that PGE1-mediated suppression of disease correlates with a dose-dependent and reversible inhibition of effector T cell differentiation. This inhibition, in turn, is mediated by PGEIinduced soluble spleen cell products that can be overcome with exogenous interleukin 1 (IL-1). In vivo administration ofprostaglandins. Groups of mice immunized to produce interstitial nephritis were injected intraperitoneally with (155) 15-methyl PGEJ, or PGF2, (12 Assessment ofrenal disease in immunized mice. Kidneys were harvested from groups of mice 10 wk after immunization. Kidney tissue was prepared for immunofluorescent and light microscopy by standard methods for this laboratory (12) . Direct immunofluorescence of tubular staining by aTBM-Ab was qualitatively graded from 0 to 4+ and expressed as a mean±SEM for each group (12) . Kidneys fixed in 10% formalin were sectioned and stained with hematoxylin and eosin, coded, and graded according to the extent of cortical involvement using established criteria ( 12) : 0, normal; 0.5, small focal areas of cellular infiltration; 1, cellular infiltration and tubular damage involving < 10% of the cortex; 2, involvement up to 25% of the cortex; 3, involvement of up to 50-75% of the cortex; and 4, extensive damage involving > 75% ofthe cortex. Scores for each experimental group were averaged and expressed as a mean±SEM. Sera collected from mice at the time of killing were also assayed for presence and titer of aTBM-Ab using a solid-phase radioimmunoassay (10) . 25 yl ofSRTA (15 Mg/ml) was added to wells ofpolyvinyl chloride (PVC) microtiter plates and kept at 40C overnight. Wells were blocked with 4% bovine serum albumin, overlaid with serial dilutions of test antisera, and subsequently incubated with '251-rabbit anti-mouse
IgG. This assay is specific for aTBM-Ab (10) .
Adoptive cell transfer and measurement ofDTH to SRTA. Draining lymph node cells were harvested from groups of immunized mice 10 wk after treatment with prostaglandins. Single cell suspensions were washed, counted, and 15 X 106 donor cells per mouse were intravenously injected into naive, syngeneic recipients. In some groups these cells were T lymphocyte-depleted with monoclonal aThy-1.2 antibody (from Jlj hybridoma [16] ) and a mixture of rabbit and guinea pig complement (C 24-well plates. Their characteristics and specificity have been described (13 reactivity is eliminated by treatment of the lymph node cells With aThy-1.2 and C. These DTH-reactive cells were not functionally present in immunized mice treated with PGE1 from day 0, but were present in all other experimental groups. To examine if the absence of a DTH response in the PGE1-treated cohort was attributable to active suppression, we admixed immune lymphocytes from RTA/CFA-immunized mice with cells from mice treated with PGE1. Previous studies from our laboratory have shown that functional suppression of the DTH response can be demonstrated when suppressor cells are acutely admixed and co-transferred with DTH-reactive cells (21) . As indicated in Table II , the absence of a DTH response in the PGEI-treated group could not be attributed to active suppression.
In vitro induction of tubular antigen-reactive effector cells inhibited by PGE1. In previous studies we have described an in vitro system that induces nephritogenic effector T cells in 5-d cultures (13 (SRTA), IL-2, and irradiated SJL spleen cells in the presence of PGE1 or PGF2af. After extensive dialysis to remove the free prostaglandin, these supernatants were used as a source of ThP in the effector cell induction assay. PGE1 remaining in the supernatant after dialysis, -2 ng/ml (6 X 10-9 M) by radioimmunoassay, was added to the control flasks (18) . As shown in Table  V PGE, reversible inactivation ofeffector T cell precursors. The studies described in the preceding paragraph suggested to us that PGEI inhibited one or multiple steps of effector cell differentiation at the precursor T cell level. Conceivably such inhibition could occur by several mechanisms; an effect of prostaglandins on major histocompatibility complex (MHC) antigen expression by antigen-presenting cells (22) , lymphokine production (23-25), or a direct inhibitory effect on the precursor T cells. To test these hypotheses, we used strategies of adding back either fresh and resuspended in fresh media, 1-2, SRTA, and ThF1. In some experiments fresh spleen cells or spleen cell subpopulations were added to the cells pulsed with PGE1. * DTH response was measured as described in Table III on These strategies required eliminating exogenous PGEI from the culture media to which the splenic cell subpopulations were added. We initially established, therefore, that pulsing the naive spleen cell population with 12 sg/ml of PGEI for only the first 24 h of culture also resulted in a suppressed effector cell response when the cells were harvested 5 d later (Table VII) . When the cells were harvested 7 or 10 d after the 24-h pulse with PGEI, however, responsiveness was restored, which indicated that the PGE1 effect was temporary. Addition of fresh nonadherent, but not adherent cells, after the 24-h PGE, pulse reconstituted the DTH response by day 5. Negative selection techniques with monoclonal antibodies and C indicated that the nonadherent cell responsible for restoration of the DTH response was a T cell.
PGE1 inhibitory effects overcome by recombinant murine IL-1. Recent reports have described the down-regulation of IL-1 production by endogenously produced PGE2 and PGI2 (26, 27) . Although the PGEI concentration used in our in vitro studies exceeds by several logfold that generated endogenously, we examined the effects of recombinant IL-I on PGEI inhibition of DTH effector cell induction. As seen in Table VIII , purified recombinant IL-1, in a dose-dependent manner, eventually overcame the inhibitory effects of PGE,. Heat inactivation of the IL-I preparation abrogated its activity. PGE,-associated inhibition mediated by PGE,-induced solublefactors. Although the preceding experiment was consistent with an effect ofexogenous PGE, on IL-I production, the studies in Table VII also implicated an effect on T cells rather than antigen-presenting cells. Both Tables VII and VIII, however, were equally consistent, with a primary effect ofPGE, on T cells that secondarily resulted in suppressed IL-I production and/or diminished T cell sensitivity to secreted IL-1. Previous work by other investigators has described nonspecific T suppressor factors induced by PGEI (28) (29) (30) (31) . We tested, therefore, the ability of dialyzed supernatants from day 5 effector cell induction cultures treated with PGEI to inhibit effector cell induction. As demonstrated in Table IX , inhibition is mediated by a nondialyzable factor in these supemnatants that is not PGE1. Inhibition by these supernatants can also be overcome by recombinant murine IL-1 in a dose-dependent manner, similar to that seen in Table  VIII . 18.0±0.5' * Culture flasks were set up as described in Table III (Tables V   and VI ). The majority of our studies were done using pharmacologic PGE1 concentrations (3 X l0-5 M) unlikely to be achieved in vivo by endogenous release of PGEI (partial inhibition of effector cell induction was observed, however, at 3 X l0-M). The pharmacologic concentrations of PGEI that we used were similar to those previously shown, for example, to stimulate T cells to release the suppressor lymphokines, PITS (28) (29) (30) (31) . This heterogeneous group of suppressor factors has been shown to inhibit mitogen-induced blastogenesis (28-30), mixed lymphocyte re-actions (29) , as well as T-dependent and -independent B cell responses (29, 30) . One of the low molecular weight PITS factors may even be a leukotriene (31) . The data in-this report are consistent with PGEI indirectly mediating inhibition through induction of suppressor lymphokines (Table IX) . Our studies also suggest that synthesis and/or release ofthese PITS factors requires the continued presence of PGE1 in the media, since delayed recovery occurs after removal of PGEI (Table VII) . Addition of fresh T cells, which have not been induced to synthesize PITS factors, also accelerates recovery.
Several earlier studies of PGE1-or PGE2-mediated suppression suggested this effect was attributable in part to inhibition of IL-2 synthesis (23-25). In theory such results could also be explained by a primary inhibitory effect on IL-1 synthesis and/ or responsiveness. Coupled with more recent studies suggesting an inhibitory effect of endogenous PGEI on IL-1 production, (26, 27) these previous experiments suggested to us that exogenous PGEI (or PITS) may also act through inhibition of IL-I synthesis and/or target cell responsiveness to this lymphokine. Our results in Tables VIII and IX are consistent with this hypothesis, although they do not distinguish between the two aforementioned mechanisms. It is also possible that high concentrations of recombinant IL-1 can overcome other PGEI-related, IL-1-independent, defects in effector cell differentiation.
